NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...

Core Viewpoint - Molina Healthcare, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 5, 2025, and July 23, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements regarding Molina's "medical cost trend assumptions" and concealed adverse facts about the company's financial health [2]. - It is alleged that Molina was experiencing a dislocation between premium rates and medical costs, which could lead to a significant cut in the company's financial guidance for fiscal year 2025 [2]. - Following the revelation of these issues, Molina's stock price experienced a decline [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 2, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in CarMax, Inc. ("CarMax, Inc." or the "Company") (NYSE: KMX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of CarMax, Inc. investors who were adversely affected by alleged securities fraud between June 20, 2025 and September 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/carmax-inc-lawsuit-subm ...

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to alleged violations of federal securities laws [2][4]. Company Overview - Stride, Inc. is an education technology company that provides an online platform to students across the U.S. [5]. Allegations and Stock Impact - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students" and ignored compliance requirements, leading to a poor customer experience and higher withdrawal rates [5][6]. - On September 14, 2025, a report of fraud allegations caused Stride's stock to drop by $18.60, or over 11%, from $158.36 to $139.76 per share [6]. - Following an admission of poor customer experience on October 28, 2025, Stride's stock plummeted by $83.48, or more than 54%, from $153.53 to $70.05 per share, with an estimated impact of 10,000-15,000 fewer enrollments [7]. Legal Context - Investors have until January 12, 2026, to seek appointment as lead plaintiffs in the case, which is pending in the U.S. District Court for the Eastern District of Virginia [4]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [4]. Legal Representation - Bleichmar Fonti & Auld LLP is representing the plaintiffs in this class action and has a history of successful recoveries in similar cases [10].

INSP INVESTORS: BFA Law Reminds Inspire Medical Systems, Inc. Investors with Losses to Contact the Firm Before the Imminent January 5 Securities Class Action DeadlineNovember 20, 2025 3:46 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 20, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for s ...

Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Arizona, titled Reed v. Freeport-McMoRan Inc., et al., No. 2:25-cv-04243, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [4]. - Investors have until January 12, 2026, to request to be appointed to lead the case [4]. Group 2: Company Operations and Safety Claims - Freeport-McMoRan operates the Grasberg Copper and Gold Mine in Indonesia, where it has been accused of overstating its commitment to safety while conducting unsafe mining practices [5][6]. - The company had previously promoted its safety procedures, including the use of data and technology to prevent fatal incidents [5]. Group 3: Stock Price Impact - On September 9, 2025, Freeport's stock dropped by $2.77 per share (over 5.9%) following a press release about suspended mining operations due to a landslide [7]. - Following updates on September 24, 2025, regarding fatalities and operational suspensions, the stock fell by $7.69 per share (almost 17%) [8]. - Additional reports on September 25, 2025, regarding strained relations with the Indonesian government led to a further decline of $2.33 per share (over 6%) [10]. - A report on September 28, 2025, indicated that the landslide was preventable, further impacting investor confidence [11].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - Investors have until December 30, 2025, to request to lead the case in the U.S. District Court for the Northern District of California [3]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Company Performance - Synopsys provides design automation software and has seen its Design IP segment grow from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported Q3 2025 results showing a 7.7% year-over-year decline in Design IP revenue to $425.9 million and a 43% year-over-year decline in net income to $242.5 million [6]. Group 3: Market Reaction - Following the Q3 2025 results, Synopsys stock fell nearly 36%, from $604.37 per share to $387.78 per share [6]. - The decline was attributed to customers requiring more customization for IP components, impacting the business model and economics of the Design IP segment [5][6].

BYND INVESTORS: BFA Law Reminds Beyond Meat, Inc. Investors with Losses to Contact the Firm about its Ongoing Securities Fraud InvestigationNovember 20, 2025 3:41 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 20, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Beyond Meat, Inc. (NASDAQ: BYND) for potential violations of the federal securities laws. If you invested in Beyond Meat, you are encouraged to obtain ...

BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Block & Leviton reminds investors that a securities fraud lawsuit has been filed against CarMax, Inc. (NYSE: KMX) and certain of its executives. Investors who have lost money in their CarMax, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/kmx. What is this all about? Shares of CarMax fell more than 10% in pre-market trading on November 6, 2025, after the company ...

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified Class Period [1][2]. Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [2]. - The enhancements claimed for the G7 device were overstated, and the company downplayed the severity of issues related to the adulterated devices [2]. - These actions have led to increased regulatory scrutiny and potential legal, reputational, and financial harm for DexCom [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case [3]. Contact Information - Kessler Topaz Meltzer & Check, LLP encourages affected DexCom investors to reach out for more information regarding the lawsuits [4].